14.09.2010 • NewsGenzymeCredit SuisseGoldman Sachs

Genzyme to Sell Genetics Unit to Labcorp for $925 million

U.S. biotech firm Genzyme said it agreed to sell its genetic-testing business to Labcorp of America Holdings for $925 million in cash.

Genzyme, which recently rejected a takeover bid from French drugmaker Sanofi-Aventis, said its plan to divest two other units - diagnostic products and pharmaceutical intermediates - stays on track and proceeds from the deals may be used to fund the second half its $2 billion stock buyback.

In a separate statement, Labcorp said the deal has a net cash cost of about $795 million to the medical-testing company. Labcorp said it obtained a funding commitment from Citi to provide debt financing for the transaction.

Labcorp will buy the entire business, called Genzyme Genetics, including all testing services, technology, intellectual property rights and testing laboratories.

Labcorp also committed to offer jobs to the unit's nearly 1,900 employees, including senior management, upon closing, Genzyme said. Genzyme Genetics had revenue of $371 million in 2009. In May, Genzyme had said it would try to sell its three noncore businesses in
an effort to win back investors' confidence.

Cambridge, Massachusetts-based Genzyme was advised by Credit Suisse and Goldman Sachs, while Citi and Lazard acted as
financial advisers to Labcorp.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.